CA Patent

CA2906732C — Lipid nanoparticles for transfection and related methods

Assigned to University of British Columbia · Expires 2023-08-08 · 3y expired

What this patent protects

ABSTRACT Transfection reagent compositions are provided, comprising (a) 1,17-bis(2-octylcyclopropyl)heptadecan-9-y1-4-(dimethylamino)butanoate, or pharmaceutically acceptable salts thereof; (b) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); (c) cholesterol; and (d) one or mor…

USPTO Abstract

ABSTRACT Transfection reagent compositions are provided, comprising (a) 1,17-bis(2-octylcyclopropyl)heptadecan-9-y1-4-(dimethylamino)butanoate, or pharmaceutically acceptable salts thereof; (b) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); (c) cholesterol; and (d) one or more surfactants selected from polyoxyethylene (20) oleyl ether, polyoxyethylene (23) lauryl ether, or polyethylene (40) stearate. Lipid nanoparticles prepared from the transfection reagent composition, kits that include the transfection reagent composition, and methods for making and using lipid nanoparticles prepared from the transfection reagent composition are also provided. CAN_DMS: \138063613\1 Date Recue/Date Received 2021-02-23

Drugs covered by this patent

Patent Metadata

Patent number
CA2906732C
Jurisdiction
CA
Classification
—
Expires
2023-08-08
Drug substance claim
No
Drug product claim
No
Assignee
University of British Columbia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.